GLMD
NASDAQ · Biotechnology
Galmed Pharmaceuticals Ltd
$0.53
-0.03 (-5.18%)
Open$0.54
Previous Close$0.56
Day High$0.57
Day Low$0.53
52W High$1.65
52W Low$0.41
Volume—
Avg Volume381.2K
Market Cap4.95M
P/E Ratio—
EPS$-2.07
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,148.6% upside
Current
$0.53
$0.53
Target
$17.25
$17.25
$9.83
$17.25 avg
$23.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.77M | 1.41M |
| Net Income | 137.6K | 142.0K | 102.7K |
| Profit Margin | 8.1% | 8.0% | 7.3% |
| EBITDA | 176.3K | 217.6K | 150.4K |
| Free Cash Flow | 176.3K | 155.0K | 130.1K |
| Rev Growth | +12.1% | -7.4% | -2.7% |
| Debt/Equity | 1.54 | 1.34 | 1.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |